Sun Pharma gains on higher prices for drugs
Reuters Market Eye - Shares in Sun Pharmaceutical Industries(SUN.NS) gain 1.8 percent after Credit Suisse said the drug maker's subsidiary Taro Pharmaceutical Industries (TARO.N) has pushed through price increases in three products last week, citing industry checks.
Credit Suisse estimates those three drugs account for 35 percent of Taro U.S. sales.
The price increases raise sustainable sales estimates for Taro to $680 million versus $640 million earlier for FY 2015, the investment bank adds.
Credit Suisse maintains its "outperform" rating on the stock and raises its target price to 900 rupees from 840 rupees, in part by factoring higher sales estimates for Taro.
(Reporting by Abhishek Vishnoi)
- Tweet this
- Share this
- Digg this
- Twelve-hour cease-fire takes effect between Israel, Gaza militants
- India threatens to derail WTO deal, prompts angry U.S. rebuke
- Israel rejects Gaza ceasefire plan, wants changes - govt source
- UPDATE 1-Former Bear Stearns chairman Greenberg dead at 86
- 'Weird Al' Yankovic still trying to wrap head around No. 1 album
A 12-hour humanitarian truce went into effect on Saturday after Israel and Palestinian militant groups in the Gaza Strip agreed to a U.N. request for a pause in fighting and efforts proceeded to secure a long-term cease-fire moved ahead. Full Article
Amazon's far-reaching ambitions, lack of profits, unnerve investors Full Article